MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Waters Corporation Operating Income 2011-2026 | WAT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Waters Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 271 M | 292 M | 818 M | 873 M | 822 M | 645 M | 708 M | 740 M | 662 M | 625 M | 567 M | 518 M | 517 M | 511 M | 529 M | 450 M | 395 M | 390 M | 349 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 873 M | 271 M | 562 M |
Quarterly Operating Income Waters Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47 M | 192 M | 188 M | 152 M | - | 211 M | 189 M | 134 M | - | 179 M | 200 M | 174 M | - | 192 M | - | 195 M | 262 M | 192 M | 196 M | 171 M | 264 M | 158 M | 155 M | 68.3 M | 236 M | 173 M | 178 M | 121 M | 245 M | 172 M | 179 M | 144 M | 231 M | 159 M | 154 M | 119 M | 208 M | 152 M | 152 M | 113 M | 181 M | 136 M | 130 M | 120 M | 172 M | 139 M | 118 M | 88.8 M | 176 M | 119 M | 113 M | 109 M | 159 M | 122 M | 120 M | 110 M | 165 M | 127 M | 121 M | 116 M | 104 M | 106 M | 92.4 M | 96.1 M | 86.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | -47 M | 152 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.26 | -7.0 % | $ 181 M |  China |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.34 | -17.79 % | $ 1.78 M |  USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.78 | -2.53 % | $ 477 M | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 112.09 | -1.02 % | $ 34.1 B | USA |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 19.05 | 0.9 % | $ 552 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 139.97 | -2.28 % | $ 22.3 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 19.83 | -3.22 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 94.74 | -2.0 % | $ 6.39 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 419.82 | 0.16 % | $ 12.1 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 3.6 | -0.69 % | $ 333 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
NeoGenomics
NEO
|
-116 M | $ 8.28 | -0.96 % | $ 1.06 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 18.46 | -2.48 % | $ 413 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 157.18 | -1.33 % | $ 7.79 B | USA |
 |
Natera
NTRA
|
-541 M | $ 186.22 | -5.43 % | $ 18.3 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 25.27 | -0.94 % | $ 24 B |  Niderland |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 92.95 | -5.79 % | $ 11.7 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.73 | -1.55 % | $ 239 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 6.47 | -3.64 % | $ 577 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 117.95 | 0.73 % | $ 9.73 B |  Irlanda |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.99 | -0.01 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 49.3 | -6.89 % | $ 2.95 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.31 | -4.04 % | $ 5.31 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 251.18 | -1.12 % | $ 20.9 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 439.31 | -1.97 % | $ 166 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.57 | -1.49 % | $ 205 M | Irlanda |
 |
Celcuity
CELC
|
-172 M | $ 134.9 | 0.13 % | $ 6.31 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.27 | -1.9 % | $ 1.79 B | USA |